Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) and Inmagene Biopharmaceuticals (“Inmagene”) announced they have entered into a definitive merger agreement. In connection with the merger, Ikena has entered into subscription agreements for a $75 million private placement (the “Financing”) with a syndicate that includes new investors such as Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors such as BVF Partners L.P., Blue Owl Healthcare Opportunities, Omega Funds, and OrbiMed. The combined company will focus on the development of IMG-007, a monoclonal antibody (mAb) targeting OX40, for the treatment of atopic dermatitis.
Read the full article: Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement //
Source: https://www.globenewswire.com/news-release/2024/12/23/3001242/0/en/Ikena-Oncology-and-Inmagene-Biopharmaceuticals-Announce-Agreement-for-Merger-and-Private-Placement.html